These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25363327)

  • 41. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir.
    Borzacov LM; de Figueiredo Nicolete LD; Souza LF; Dos Santos AO; Vieira DS; Salcedo JM
    Int J Infect Dis; 2016 May; 46():82-8. PubMed ID: 27005283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus.
    Wolters LM; van Nunen AB; Honkoop P; Vossen AC; Niesters HG; Zondervan PE; de Man RA
    J Viral Hepat; 2000 Nov; 7(6):428-34. PubMed ID: 11115054
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 44. Predicting treatment outcomes for HBV patients.
    AIDS Patient Care STDS; 2009 Mar; 23(3):223. PubMed ID: 19480059
    [No Abstract]   [Full Text] [Related]  

  • 45. Interferon lambda-3 polymorphism and response to pegylated interferon in patients with hepatitis D.
    Abbas Z; Yakoob J; Umer MA; Abbas M; Hamid S
    Antivir Ther; 2015; 20(5):529-33. PubMed ID: 25668821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymorphisms in the IL28B gene (rs12979860, rs8099917) and the virological response to pegylated interferon therapy in hepatitis D virus patients.
    Yilmaz B; Can G; Ucmak F; Arslan AO; Solmaz I; Unlu O; Düzenli S; Korkmaz U; Kurt M; Senates E
    Acta Gastroenterol Belg; 2016; 79(2):206-10. PubMed ID: 27382939
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Advance in clinical studies of the kinetics of hepatitis B virus].
    Tang YT; Cao Q; Zhang DZ
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
    [No Abstract]   [Full Text] [Related]  

  • 48. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients.
    Franco S; Tural C; Clotet B; Martinez MA
    AIDS; 2012 Sep; 26(15):1973-4. PubMed ID: 22992578
    [No Abstract]   [Full Text] [Related]  

  • 50. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis B surface antigen quantification as a current-day paradox: obtaining the gold in the face of diminishing returns.
    Perrillo RP
    Hepatology; 2009 Apr; 49(4):1063-5. PubMed ID: 19330864
    [No Abstract]   [Full Text] [Related]  

  • 53. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa.
    Yeh ML; Huang JF; Yu ML; Chuang WL
    Expert Rev Gastroenterol Hepatol; 2021 Apr; 15(4):427-435. PubMed ID: 33338385
    [No Abstract]   [Full Text] [Related]  

  • 54. Hepatitis C virus kinetics by administration of pegylated interferon-α in human and chimeric mice carrying human hepatocytes with variants of the IL28B gene.
    Watanabe T; Sugauchi F; Tanaka Y; Matsuura K; Yatsuhashi H; Murakami S; Iijima S; Iio E; Sugiyama M; Shimada T; Kakuni M; Kohara M; Mizokami M
    Gut; 2013 Sep; 62(9):1340-6. PubMed ID: 23135762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Peginterferon for chronic hepatitis B: predicting success with on-treatment benchmarks.
    Moucari R
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1474-5. PubMed ID: 20796141
    [No Abstract]   [Full Text] [Related]  

  • 56. An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity: the future of chronic hepatitis B?
    Wu D; Han M; Ning Q
    J Hepatol; 2015 Jan; 62(1):240-1. PubMed ID: 25308175
    [No Abstract]   [Full Text] [Related]  

  • 57. Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b.
    Venezia G; Licata A; Di Marco V; Craxì A; Almasio PL
    Dig Liver Dis; 2005 Nov; 37(11):882-5. PubMed ID: 16169301
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine.
    Mansour W; Ducancelle A; Le Gal F; Le Guillou-Guillemette H; Abgueguen P; Pivert A; Calès P; Gordien E; Lunel F
    J Clin Virol; 2010 Jan; 47(1):97-9. PubMed ID: 19914127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical significance of 4 patients with chronic hepatitis B achieving HBsAg clearance by treated with pegylated interferon alpha-2a for less than 1 year: a short report.
    Yang J; Zhao LS
    Virol J; 2009 Jul; 6():97. PubMed ID: 19583877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
    J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.